Last updated: November 5, 2026
Wainua, the brand name for eplontersen, is AstraZeneca and Ionis Pharmaceuticals’ monthly subcutaneous antisense therapy for hereditary transthyretin-mediated amyloid polyneuropathy, or hATTR-PN. The FDA approved Wainua on December 21, 2023. Its autoinjector format gives the product a commercial advantage over infusion-based therapies, but it enters a market with established RNA-targeted competitors, including Amvuttra, Onpattro, and Tegsedi.[1]
Wainua’s financial trajectory is still in the launch phase. AstraZeneca and Ionis had not reported a mature, standalone Wainua revenue stream in the publicly available reporting through mid-2024. Near-term value depends on U.S. uptake, payer coverage, diagnosis of hereditary disease, conversion from competing therapies, and international regulatory approvals.
What is Wainua autoinjector and how does it work?
Wainua is a prescription antisense oligonucleotide containing eplontersen. It targets transthyretin messenger RNA in the liver and reduces production of both mutant and wild-type transthyretin protein.
| Product attribute |
Wainua |
| Active ingredient |
Eplontersen |
| Drug class |
Antisense oligonucleotide |
| Target |
Transthyretin, or TTR, mRNA |
| Approved indication |
Polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults |
| Administration |
45 mg subcutaneous injection once monthly |
| Delivery |
Single-dose autoinjector |
| U.S. approval |
December 21, 2023 |
| U.S. commercial partners |
AstraZeneca and Ionis Pharmaceuticals |
| Loading regimen |
None under the U.S. prescribing information |
| Key clinical study |
NEURO-TTRansform |
| Primary efficacy measure |
Change in modified Neuropathy Impairment Score +7 |
Wainua’s monthly schedule is less frequent than daily oral tafamidis and more convenient than clinic-administered infusion products. The autoinjector also supports administration by patients or caregivers after training.[1]
What is the FDA regulatory status of Wainua?
The FDA approved Wainua through the standard New Drug Application pathway. The approval was based primarily on the NEURO-TTRansform study, a global Phase 3 trial evaluating eplontersen in patients with hereditary transthyretin-mediated polyneuropathy.[1]
The FDA label identifies reductions in serum transthyretin as a pharmacodynamic effect and supports the drug’s use in adult patients with hATTR-PN. The approval does not cover wild-type transthyretin amyloidosis or cardiomyopathy as a standalone indication.
Wainua’s regulatory expansion opportunity is transthyretin amyloid cardiomyopathy, or ATTR-CM. That indication is commercially important because ATTR-CM has a larger diagnosed and potentially treatable population than hATTR-PN. As of the available public information through mid-2024, Wainua did not have an FDA approval for ATTR-CM.
Key FDA milestones
| Date |
Event |
| October 2021 |
Ionis and AstraZeneca entered a strategic agreement covering eplontersen development and commercialization |
| 2022 |
NEURO-TTRansform Phase 3 data supported the regulatory package |
| December 21, 2023 |
FDA approved Wainua for adult hATTR-PN |
| 2024 |
U.S. commercial launch and payer-access activities began |
How large is the Wainua market?
The addressable market is constrained by the rarity of hATTR-PN but supported by high treatment value and chronic duration. Patients generally require long-term therapy, creating recurring revenue when treatment persistence is strong.
Market expansion depends on five factors:
- Genetic testing and disease diagnosis.
- Earlier referral to amyloidosis centers.
- Reimbursement for high-cost specialty medicines.
- Switching from infusion or older RNA therapies.
- Expansion into ATTR-CM.
The commercial market is concentrated in the United States, Western Europe, Japan, and selected specialist markets. The U.S. has the strongest near-term revenue potential because it has a large specialty-pharmacy infrastructure and broad adoption of high-cost orphan drugs.
Wainua competes in a market where disease prevalence is likely undercounted. ATTR disease can resemble diabetic neuropathy, chronic inflammatory demyelinating polyneuropathy, or other neurological disorders. Delayed diagnosis reduces the immediate addressable population but creates an opportunity for market growth as genetic and tissue-based testing improves.
How does Wainua compare with competing transthyretin drugs?
Wainua’s primary competitors are Amvuttra, Onpattro, Tegsedi, and tafamidis products. Each has a different treatment profile and commercial position.
| Product |
Active ingredient |
Company |
Administration |
Main commercial advantage |
| Wainua |
Eplontersen |
AstraZeneca/Ionis |
Monthly subcutaneous autoinjector |
Patient-administered monthly dosing |
| Amvuttra |
Vutrisiran |
Alnylam |
Subcutaneous injection every three months |
Less frequent dosing |
| Onpattro |
Patisiran |
Alnylam |
Intravenous infusion every three weeks |
Established RNAi efficacy and market presence |
| Tegsedi |
Inotersen |
Ionis |
Subcutaneous injection, generally weekly |
Earlier antisense entrant |
| Vyndaqel/Vyndamax |
Tafamidis |
Pfizer |
Daily oral capsule |
Strong ATTR-CM position and oral dosing |
Wainua’s most direct competitive challenge is Amvuttra. Both products use subcutaneous administration and target transthyretin production. Amvuttra has a quarterly dosing schedule, which may be more attractive to some patients and physicians than monthly administration.
Wainua’s main product advantages are the autoinjector format, monthly dosing, and AstraZeneca’s global commercial infrastructure. Its main disadvantage is later entry into a market where Alnylam has established physician relationships and reimbursement experience.
What are Wainua’s financial prospects?
Wainua is unlikely to produce material revenue immediately after launch because the commercial ramp requires diagnosis, specialty-center adoption, payer contracting, and patient onboarding. The product has the potential to become a significant specialty asset if it expands beyond hATTR-PN.
Revenue drivers
The principal revenue drivers are:
- Net price after rebates and discounts.
- Number of diagnosed hATTR-PN patients.
- Treatment initiation rate.
- Persistence on monthly therapy.
- Conversion from Tegsedi, Onpattro, or Amvuttra.
- Use in additional geographic markets.
- Approval for ATTR-CM.
- Expansion of genetic screening.
Because Wainua is an orphan specialty drug administered chronically, revenue can scale without requiring mass-market prescribing. However, the product needs a growing diagnosed population because hATTR-PN is rare and competing therapies have already treated many identifiable patients.
Revenue risks
The principal financial risks are:
- Quarterly dosing from Amvuttra.
- Tafamidis’ established role in ATTR-CM.
- Payer restrictions and prior authorization.
- High patient-acquisition costs.
- Limited physician familiarity with eplontersen.
- Safety monitoring and treatment discontinuation.
- Delays in cardiomyopathy development.
- Potential future price competition among RNA-targeted therapies.
Neither AstraZeneca nor Ionis had disclosed a mature standalone Wainua revenue history in the public sources available through mid-2024. Consequently, the product’s commercial trajectory should be assessed through launch metrics, prescription volume, patient starts, payer coverage, and regulatory expansion rather than historical sales growth.
Who owns Wainua and how are the economics divided?
AstraZeneca and Ionis entered a strategic collaboration for eplontersen in 2021. AstraZeneca assumed responsibility for global development, regulatory submissions, and commercialization outside specified Ionis territories. Ionis retains an economic interest through the collaboration and is eligible for milestone payments and royalties under the agreement.[2]
The arrangement gives Wainua access to AstraZeneca’s cardiovascular and specialty-care infrastructure while preserving Ionis’ participation in long-term product economics. The exact royalty and milestone terms are governed by the agreement and are not fully reflected in product-level public reporting.
The partnership reduces the commercial burden on Ionis but also means that Wainua’s reported economics may be distributed across collaboration revenue, royalties, milestone payments, and product sales rather than reported as a simple consolidated product line.
What patents protect Wainua autoinjector?
Wainua’s protection is expected to come from several layers of intellectual property:
- Eplontersen composition and sequence claims.
- Antisense chemistry and conjugate claims.
- TTR-targeting methods.
- Treatment methods for hATTR-PN.
- Dosing and administration regimens.
- Formulation and stability claims.
- Device and autoinjector rights.
- Manufacturing processes for the oligonucleotide.
The strongest commercial protection generally comes from composition-of-matter and sequence-specific claims. Formulation, dosing, and device patents can extend practical barriers but are more vulnerable to design-around strategies.
The Orange Book status of Wainua should be reviewed against the current FDA Approved Drug Products with Therapeutic Equivalence Evaluations database. Publicly available information through mid-2024 did not establish a complete, authoritative list of Wainua patent numbers and expiration dates suitable for a definitive loss-of-exclusivity forecast. Patent-term calculations for oligonucleotide products also depend on prosecution history, patent-term adjustment, patent-term extension, terminal disclaimers, and regulatory exclusivity.
Patent strength assessment
| Patent layer |
Commercial importance |
General vulnerability |
| Active sequence or composition |
Very high |
Invalidity and claim-construction challenges |
| Conjugate or chemical modification |
High |
Design-around chemistry |
| hATTR-PN method of use |
High in labeled indication |
Label carve-outs and off-label prescribing |
| Monthly dosing regimen |
Medium |
Obviousness and prior-art challenges |
| Formulation |
Medium |
Alternative excipients and concentration |
| Autoinjector device |
Medium |
Competing delivery systems |
| Manufacturing process |
Medium to high |
Trade-secret protection may be stronger than patent protection |
When does Wainua lose exclusivity?
A definitive Wainua loss-of-exclusivity date cannot be stated from the available public information without a verified list of issued patents, Orange Book entries, patent-term adjustments, and regulatory exclusivity periods.
FDA approval gives Wainua regulatory protection separate from patent rights. The product may benefit from orphan-drug exclusivity for the approved indication, subject to the scope and duration of the designation. Orphan exclusivity generally restricts approval of the same drug for the same disease or condition for seven years in the United States, although it does not block all competing products or different indications.[3]
Patent protection may last beyond orphan exclusivity. Generic competition would also depend on the FDA’s treatment of eplontersen, the existence of an approved abbreviated pathway, and the ability of a challenger to address listed patents.
What generic entry risks exist for Wainua?
Near-term generic erosion risk is low. Wainua is an injectable antisense oligonucleotide with specialized chemistry, manufacturing requirements, and a relatively small patient population.
A future challenger would face several barriers:
- Demonstrating pharmaceutical equivalence.
- Characterizing complex oligonucleotide chemistry.
- Matching the delivery system or providing an acceptable alternative.
- Establishing quality and impurity controls.
- Addressing listed patents.
- Obtaining access to specialized manufacturing capacity.
- Navigating a small, specialist prescriber base.
The more immediate competitive threat is not a traditional generic. It is substitution by another branded RNA-targeted therapy, especially Amvuttra, or by a future TTR silencer approved for ATTR-CM.
Which companies are challenging Wainua commercially?
Alnylam is Wainua’s most important branded competitor. Its Amvuttra product has a three-month dosing interval and is positioned across transthyretin amyloidosis treatment settings. Pfizer has a strong commercial position in ATTR-CM through Vyndaqel and Vyndamax. Ionis also competes with its own Tegsedi product, creating potential portfolio substitution but also allowing the company to shift patients toward its newer partnered asset.
The competitive landscape is therefore divided by disease phenotype and administration:
- hATTR-PN: Wainua, Amvuttra, Tegsedi, and Onpattro.
- ATTR-CM: Vyndaqel/Vyndamax, Amvuttra, and pipeline RNA-targeted therapies.
- Patient preference: oral daily, monthly autoinjector, quarterly injection, or clinic infusion.
What launch scenarios could affect Wainua revenue?
Base case
Wainua gains gradual adoption in hATTR-PN, particularly among patients seeking a self-administered alternative to infusion therapy. Revenue grows steadily but remains below the level of established competitors because the indication is narrow.
Upside case
The product obtains ATTR-CM approval, secures broad payer access, and demonstrates strong cardiovascular outcomes. Monthly autoinjector delivery becomes a preferred option for patients who want home administration. This scenario materially expands the addressable market.
Downside case
Amvuttra maintains strong physician and payer preference because of quarterly dosing. Wainua remains limited to hATTR-PN, and uptake is concentrated in treatment switching rather than new diagnosis. Revenue remains a modest specialty-product contribution.
What manufacturing and supply-chain barriers affect Wainua?
Wainua requires specialized oligonucleotide manufacturing, purification, analytical testing, sterile fill-finish, and autoinjector assembly. Scale-up is more complex than for conventional small-molecule tablets.
Key supply risks include:
- Capacity for large-scale oligonucleotide synthesis.
- Batch consistency and impurity control.
- Sterile injectable production.
- Device component availability.
- Cold-chain and specialty-pharmacy distribution.
- Dependence on qualified contract manufacturing sites.
Manufacturing know-how can create a practical barrier even where patent claims are narrow. The combination of chemistry, analytical methods, and device assembly makes rapid generic replication difficult.
How strong is Wainua’s commercial position?
Wainua has a credible but not dominant market position. Its strongest assets are the monthly autoinjector, AstraZeneca’s global infrastructure, Ionis’ antisense expertise, and the potential for expansion into ATTR-CM.
Its principal weaknesses are later market entry, a narrow initial label, competition from quarterly Amvuttra, and the absence of a mature standalone revenue record. The product’s long-term value depends less on hATTR-PN alone than on whether the partners can establish eplontersen as a broader transthyretin amyloidosis therapy.
Key Takeaways
- Wainua is a monthly 45 mg eplontersen autoinjector approved for adult hATTR-PN.
- AstraZeneca and Ionis commercialize the product through a strategic collaboration.
- Amvuttra is the closest branded competitor because it also uses subcutaneous administration and targets TTR production.
- Wainua’s initial market is limited by the rarity and underdiagnosis of hATTR-PN.
- ATTR-CM is the main opportunity for material market expansion.
- Standalone Wainua revenue was not yet mature or separately disclosed in the public reporting available through mid-2024.
- Near-term generic risk is low because of complex oligonucleotide chemistry, manufacturing, and delivery requirements.
- The definitive patent-expiration date requires a verified current patent and Orange Book review.
- Wainua’s upside depends on payer access, patient switching, diagnosis growth, and additional indications.
FAQs
Is Wainua an oral drug?
No. Wainua is administered as a 45 mg subcutaneous injection once monthly using a single-dose autoinjector.
Is Wainua the same as Tegsedi?
No. Both are Ionis-related antisense therapies that reduce TTR production, but Wainua uses eplontersen and monthly dosing, while Tegsedi uses inotersen and has a different dosing and monitoring profile.
Can Wainua be used for ATTR cardiomyopathy?
The initial FDA approval covers polyneuropathy of hereditary transthyretin-mediated amyloidosis. Use for ATTR-CM requires an applicable regulatory approval and should not be inferred from the hATTR-PN label.
What is Wainua’s main commercial competitor?
Amvuttra is the closest commercial competitor because it is a subcutaneous TTR-silencing therapy with less frequent dosing. Tafamidis is the major competitor in ATTR-CM.
Does Wainua have biosimilar competition?
No. Wainua is a chemically synthesized antisense oligonucleotide rather than a conventional biologic protein. Any future competitor would likely follow a complex generic or hybrid regulatory pathway rather than a standard biosimilar pathway.
References
-
U.S. Food and Drug Administration. (2023). Wainua prescribing information: Eplontersen injection. FDA.
-
Ionis Pharmaceuticals, Inc. (2021). Ionis and AstraZeneca enter agreement to develop and commercialize eplontersen. Ionis Pharmaceuticals.
-
U.S. Food and Drug Administration. (2023). Designating orphan products: Drugs for rare diseases. FDA.